Take­da, Abing­worth pro­vide a $100M bankroll for an up­start T cell play­er, build­ing in a buy­out op­tion

Over the past year Take­da has been rip­ping up its old glob­al R&D or­ga­ni­za­tion and cre­at­ing a new one, with a whole new set of col­lab­o­ra­tors. To­day it’s tak­ing a front row seat at a Lon­don-based start­up, pitch­ing in on a $100 mil­lion pack­age to bankroll the con­struc­tion of Gam­maDelta Ther­a­peu­tics’ T cell plat­form while tak­ing an op­tion to ac­quire the biotech.

Things are mov­ing fast at Gam­maDelta, which has some mar­quee Gold­en Tri­an­gle names be­hind it. Take­da and its ven­ture backer Abing­worth are putting in the cash, with Take­da get­ting an eq­ui­ty stake along with its buy­out op­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER